What is Drugs Made In America Acquisition Corp.'s (DMAA) StockRank?

MoatMap's StockRank for Drugs Made In America Acquisition Corp. (DMAA) is 15/100, with a Strong Sell signal. This is a composite score combining Quality (18), Value (32), and Momentum (52) factor ranks across MoatMap's 20,000+ stock universe.

Does Drugs Made In America Acquisition Corp. have an economic moat?

Drugs Made In America Acquisition Corp. (DMAA) has a Quality factor score of 18/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Drugs Made In America Acquisition Corp. a buy, hold, or sell?

MoatMap's current signal for Drugs Made In America Acquisition Corp. (DMAA) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Drugs Made In America Acquisition Corp. in?

Drugs Made In America Acquisition Corp. (DMAA) operates in the Financial Services sector, specifically the Shell Companies industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DMAA

STRONG SELLREMOVE

Drugs Made In America Acquisition Corp. · Financial Services · United States · $257M · Avg Vol: $364K/d

StockRank

P/E (TTM)

53.1x

ROE

—

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Drugs Made In America Acquisition Corp is a blank check company (SPAC). It has no operating history, no cash flows, and no structural moat, making it entirely unsuitable for a high-conviction portfolio focused on quality compounders.

COMPANY DESCRIPTION

Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. The company currently possesses no active business operations, acting solely as a vehicle to acquire a private operating company. It represents an investment opportunity tied to the successful identification and execution of a de-SPAC transaction, likely focused on the pharmaceutical or biotechnology sector.

FINANCIAL SUMMARY (USD)

Year	2025
Revenue	0
EPS	0.19
Shares	34M
Debt	7M
Equity	233M
Op CF	-539,187
Inv CF	-231M
Fin CF	232M

PRICE (1M)+0.3%

SMA 50SMA 200

$10.63

RSI (14)

62.5

52W High

$10.63

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

-1.2%6.7

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%12.9

FCF/Assets

-0.6%22.6

Piotroski

—20.6

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

0.03x1.5

Value

P/E (TTM)

53.1x6.1

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

-49.4x98.4

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

100%99.3

RS 6M

-8%46.6

SMA 50/200

1.01x43.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$257M

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of DMAA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DMAA	Drugs Made In America Acquisition Corp.(you)	$257M	15	STRONG SELL
RAAQ	Real Asset Acquisition Corp.	$262M	15	STRONG SELL
PLMK	Plum Acquisition Corp. IV	$258M	14	STRONG SELL
DAAQ	Digital Asset Acquisition Corp.	$237M	15	STRONG SELL
VNME	Vendome Acquisition Corporation I	$255M	13	STRONG SELL
TDAC	Translational Development Acquisition Corp.	$236M	14	STRONG SELL
OACC	Oaktree Acquisition Corp. III Life Sciences	$263M	13	STRONG SELL
MACI	Melar Acquisition Corp. I	$234M	13	STRONG SELL
AACB	Artius II Acquisition Inc.	$289M	14	STRONG SELL
ALDF	Aldel Financial II Inc.	$318M	15	STRONG SELL

Peer medians: ROE 10.8% · P/E 13.6x · Gross margin 0.0%

Drugs Made In America Acquisition Corp. (DMAA) — Stock Score Summary

Drugs Made In America Acquisition Corp. (DMAA) has a MoatMap StockRank of 15/100 based on Quality (18/100), Value (32/100), and Momentum (52/100) factor scores. The current signal is STRONG SELL. Drugs Made In America Acquisition Corp is a blank check company (SPAC). It has no operating history, no cash flows, and no structural moat, making it entirely unsuitable for a high-conviction portfolio focused on quality compounders.

Key Financial Metrics

Price	$10.63
Market Cap	$257M
P/E (TTM)	53.07
Price/Book	-49.37
Return on Invested Capital	-1.2%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-2M

Drugs Made In America Acquisition Corp. operates in the Shell Companies industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Drugs Made In America Acquisition Corp.’s (DMAA) StockRank?: MoatMap’s StockRank for Drugs Made In America Acquisition Corp. (DMAA) is 15/100, with a Strong Sell signal. It is a composite of Quality (18), Value (32), and Momentum (52) factor ranks across MoatMap’s 20,000+ stock universe.
Does Drugs Made In America Acquisition Corp. have an economic moat?: Drugs Made In America Acquisition Corp. (DMAA) has a Quality factor score of 18/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Drugs Made In America Acquisition Corp. a buy, hold, or sell?: MoatMap’s current signal for Drugs Made In America Acquisition Corp. (DMAA) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Drugs Made In America Acquisition Corp. in?: Drugs Made In America Acquisition Corp. (DMAA) operates in the Financial Services sector, specifically the Shell Companies industry (United States).